Subscription Required

Only paid subscribers* to Specialty Pharmacy News can access this Web portal with three years of back issues, searchable article archives and other valuable resources.

Subscribers to Specialty Pharmacy News receive

  • 12 monthly issues packed with news and strategies on this increasingly vital sector in health business, delivered First Class by U.S. Mail and electronically (optional),
  • E-News Alerts whenever important news breaks, and
  • Access to a subscriber-only Web page with:
    • Searchable archives of past articles,
    • Convenient library with PDFs of back issues,
    • Recent stories of interest and hot topic articles grouped for convenient reading, and
    • Regular postings from Managing Editor Angela Maas.
View a sample and get more information
December 2014

Recent Stories of Interest

From Specialty Pharmacy News - Outrage over the prices of new hepatitis C therapies continues to mount, showing no sign of slowing. While the therapies are much more effective and have less severe side effects than previous treatments, their prices have prompted a range of responses from various stakeholders (SPN 11/14, p. 7). And amidst the din, one transit agency has taken the somewhat surprising step of filing a class-action lawsuit against manufacturer Gilead Sciences, Inc. Read more

With prices for biologics eating up more and more of payers’ budgets,… Read more

One Blues plan recently began a partnership with a physician group that… Read more

Orphan drugs likely do not figure prominently on health plans’ radars. After… Read more

From the Editor

Welcome to your Specialty Pharmacy News subscriber-only Web page

Be sure to visit often, for PDFs of issues, archives of articles and data, and more!

Please e-mail me with your comments on the last issue of Specialty Pharmacy News, story ideas for future issues, or any other suggestions you have that can make the newsletter more useful for you.

December 19, 2014
FDA Approves AbbVie Hepatitis C Therapy

FDA approves AbbVie’s oral hepatitis C combination treatment Viekira Pak; drug has breakthrough-therapy and prior-review designation. This is the fourth hep C drug the FDA has approved in 13 months

December 19, 2014
FDA Approves Drug, Companion Diagnostic for Ovarian Cancer

FDA gives accelerated approval to AstraZeneca’s PARP inhibitor Lynparza (olaparib) for advanced ovarian cancer, approves Myriad Genetics’ BRACAnalysis CDx as companion diagnostic

December 17, 2014
Federal Appeals Court Rules Against Myriad Genetics

Federal appeals court says three Myriad BRCA test patents should not have been granted; company cannot block other BRCA tests, which can remain on the market

Updated Regularly

Featured Hot Topics

Search for your own Hot Topics

It's quick and easy to sign up for FREE access to!

Why do I need to register?